Targeting S100A2 for Neurodegenerative Diseases (G401475)

Target Name: SRRM1P1

NCBI ID: G401475

Other Name(s): serine/arginine repetitive matrix 1 pseudogene 1 | SRRM1L | Serine/arginine repetitive matrix 1 pseudogene 1 | SRRM1P

Targeting S100A2 for Neurodegenerative Diseases

SRRM1P1, also known as serine/arginine repetitive matrix 1 pseudogene 1, is a gene that has been identified as a potential drug target or biomarker in the field of neurodegenerative diseases. The gene is located on chromosome 12q34 and encodes a protein known as S100A2, which is a key regulator of the microtubules that organize brain cells.

Studies have shown that S100A2 is highly expressed in the brains of individuals with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, the levels of S100A2 have been shown to be elevated in the brains of individuals with certain psychiatric disorders, such as depression and anxiety.

The potential drug target for SRRM1P1 is the S100A2 protein, which is known to play a role in the development and progression of neurodegenerative diseases. By targeting S100A2, researchers hope to reduce the levels of the protein in the brains of individuals with these diseases and slow down or even reverse the progression of the diseases.

One approach to targeting S100A2 is through the use of small molecules, such as drugs that bind to the protein. Researchers have identified a number of potential small molecules that have been shown to interact with S100A2 and may be useful as drug candidates. These small molecules include a variety of compounds, such as inhibitors of protein tyrosylation, which can modify the activity of S100A2, as well as agents that block the interaction between S100A2 and other proteins.

Another approach to targeting S100A2 is through the use of antibodies, which are proteins that recognize specific molecules in the body and can be used to deliver drugs or other treatments directly to those molecules. Researchers have generated antibodies that recognize S100A2 and are currently testing them as potential drug candidates.

While the potential drug targets for SRRM1P1 are still being explored, the research being done in this field has the potential to lead to new treatments for neurodegenerative diseases. By targeting S100A2 and other potential drug targets, researchers hope to slow down or even reverse the progression of these diseases and improve the quality of life for those affected.

Protein Name: Serine/arginine Repetitive Matrix 1 Pseudogene 1

More Common Targets